Γ

SynBioBeta Speaker

Blake Simmons

LBNL

Dir. Bio. Sys & Engg

Blake Simmons is a senior scientific leader at Lawrence Berkeley National Laboratory, where he serves as Director of the Biological Systems & Engineering Division. His work focuses on integrating biology, chemistry, and engineering to enable biomanufacturing and the production of affordable and scalable biofuels and bioproducts. Blake is the Chief Science and Technology Officer of the Joint BioEnergy Institute (JBEI, jbei.org), where he has driven advances in biomass deconstruction and conversion. He is widely recognized for translating fundamental science into scalable technologies and for bridging national-lab innovation with commercialization and deployment and is the co-founder of three startups.

SynBioBeta 2026 Tickets are Live

Confirmed Speakers

Sessions Featuring

Blake

This Year

Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS

Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.

Get a Ticket

Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS

Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.

Get a Ticket

TBD

Session lineup still growing

Get a Ticket

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Get a Ticket

Featuring

Speaker Coming Soon

Previous Speakers Include